Posttranslational modifications of the DUX4 protein impact toxic function
Authors:
Preprint
Abstract
Objective: Facioscapulohumeral muscular dystrophy (FSHD) is caused by abnormal de-repression of the transcription factor DUX4, which is toxic to muscle in vitro and in vivo . While the transcriptional targets of DUX4 are known, the regulation of DUX4 protein and the molecular consequences of this regulation are unclear. Here, we used in vitro models of FSHD to identify and characterize DUX4 posttranslational modifications (PTMs) and their impact on the toxic function of DUX4. Methods: DUX4 protein was immunoprecipitated and mass spectrometry performed to identify PTMs. We then extensively characterized DUX4 PTMs and potential enzyme modifiers using mutagenesis, proteomics and biochemical assays in human cell lines and human myoblast cell lines. Results: Our in vitro screen of DUX4 PTM mutants identified arginine methyl-null and serine/threonine phosphomimetic mutants that protected cells against DUX4-mediated toxicity and reduced the ability of DUX4 to transactivate downstream gene targets, including FSHD biomarkers. Using additional proteomics and biochemical approaches, we identified protein kinase A (PKA) and a protein arginine methyltransferase (PRMT1) as components of the DUX4 complex. Importantly, over-expression of PRKACA, a catalytic subunit of the PKA holoenzyme, mitigated DUX4 toxicity, while pharmacologic inhibition of PRMT1 protected human myoblasts from DUX4-mediated apoptosis. Interpretation: These results demonstrate that DUX4 is regulated by PTMs and that DUX4 PTMs, or associated modifying enzymes, may be druggable targets for FSHD therapy.Keywords
This publication has 42 references indexed in Scilit:
- Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findingsNeuromuscular Disorders, 2021
- PRMT1 activates myogenin transcription via MyoD arginine methylation at R121Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2019
- Early onset facioscapulohumeral dystrophy – a systematic review using individual patient dataNeuromuscular Disorders, 2017
- Arginine Methylation: The Coming of AgeMolecular Cell, 2017
- Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral DystrophyThe American Journal of Human Genetics, 2016
- Strategies to make protein serine/threonine (PP1, calcineurin) and tyrosine phosphatases (PTP1B) druggable: Achieving specificity by targeting substrate and regulatory protein interaction sitesBioorganic & Medicinal Chemistry, 2015
- Salvianolic acid A protects RPE cells against oxidative stress through activation of Nrf2/HO-1 signalingFree Radical Biology and Medicine, 2014
- Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory FactorCell Reports, 2013
- DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53‐dependent myopathy in vivoAnnals of Neurology, 2010
- The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic proteinNeuromuscular Disorders, 2007